No material corporate-specific disclosures were identified for Merck & Co. in the 30 days preceding this report's generation date of 2026-06-17. The most prominent macro development in the period was the reported interception of Iranian missiles aimed at US military forces in Kuwait, as covered by CNBC [Brief - 2026-06-09]. This geopolitical escalation introduced fresh uncertainty into broader equity markets during the period, though no direct operational or financial disclosures specific to Merck were identified in connection with that event [Brief - 2026-06-01].
For the trailing twelve months ending 2026-03-31, Merck & Co. recorded revenue of $65.77 billion, representing year-over-year growth of 4.87%. Net income over the same period was $8.94 billion, producing a net margin of 13.59%. Operating margin was reported at 0.56%. The company's P/E ratio stood at 32.44. Cash on hand was $5.33 billion against total debt of $49.12 billion. EPS on a year-over-year basis declined 185.57%, a significant contraction from the prior comparable period [SEC 10-Q - MRK - 2026-03-31].
This report was triggered by material changes in institutional positions disclosed in recent 13F filings. Citadel reduced its MRK position by 7% [SEC 13F - Citadel - Q1 2026]. AQR Capital reduced its position by 23% [SEC 13F - AQR Capital - Q1 2026]. Millennium Management recorded the largest reduction among the three filers, decreasing its position by 55% [SEC 13F - Millennium - Q1 2026]. No insider transaction data from SEC Form 4 filings was provided for the current reporting period.
The prevailing macro environment as of the report date featured a 10-year US Treasury yield of 4.47% and a 2-year yield of 4.07%, producing a normal yield curve spread of approximately 40 basis points [FRED DGS10] [FRED DGS2]. This rate configuration reflects the broader fixed-income backdrop against which large-cap pharmaceutical equities such as MRK are currently trading.